



Date: 5th September 2026

To The Listing Department National Stock Exchange of India Limited Exchange Plaza, Bandra-Kurla Complex Bandra (East) Mumbai 400 051 Stock Code : INDOCO	To The Listing Department Bombay Stock Exchange Limited Floor 25, P. J. Towers, Dalal Street, Mumbai 400 001 Stock Code : 532612
---	--

Dear Sir/Madam,

Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that United States Food and Drug Administration (USFDA) had inspected Company's manufacturing facility at Plant II (Sterile) located at Goa ("Facility") from 27th August, 2026 to 4th September, 2026. On conclusion of the inspection, the Company received seven (7) observations in Form 483.

We are addressing the observations comprehensively and will respond to the USFDA within the stipulated timeframe.

You are requested to kindly take the same on record.

Thanking you,
Yours faithfully,
For Indoco Remedies Limited



Sundeep V. Bambolkar
Jt. Managing Director
DIN: 00176613